🇺🇸 FDA
Pipeline program

R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7

U10-02-11-001

Phase 1 mab completed

Quick answer

R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7 for High-risk HPV Infection and Biopsy-proven CIN1 is a Phase 1 program (mab) at PDS Biotechnology Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
PDS Biotechnology Corp
Indication
High-risk HPV Infection and Biopsy-proven CIN1
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials